Amble Health vs. MEDVi: prices, fine print, and the honest verdict

Tirzepatide pricing

On tirzepatide, Amble Health is the cheaper program at $300 a month all-in versus MEDVi's $399 — a gap of $99 a month, $1,188 a year, at the 10 mg maintenance basis. Amble Health: $300 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. MEDVi: $399 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $249/mo (12-month plan). Prepaid terms reorder things: MEDVi at $249/mo (12-month plan) — paid up front, with the regulatory-era caveat that locked-in months deserve a read of the refund terms first.

Semaglutide pricing

Only MEDVi publishes a semaglutide price here: Semaglutide runs $299 a month all-in at the standing rate ($179 on intro/plan terms). Amble Health doesn't sell compounded semaglutide.

Transparency

Amble Health: Third-party-reported (verified 2026-08-05); dispensing pharmacy not publicly named. MEDVi: Source-verified (verified 2026-08-05); dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

Amble Health: unknown; not published. MEDVi: 12-month plan for the lowest rate; 12-month plan applies to lowest rate.

The gap, compounded over time

Here is what the $99 monthly spread between these two actually buys back over a treatment course — one month, $99; six months, $594; a year, $1,188; two years of maintenance, $2,376. Only MEDVi publishes a prepaid tier ($249/mo effective), which undercuts even Amble Health's standing $300 by $612/year — flexibility versus committed savings, cleanly posed. Every figure is the all-in maintenance basis; the arithmetic reruns from the dataset.

The 24-month ledger

Maintenance therapies deserve maintenance math: over two years at standing rates, Amble Health bills $7,200 and MEDVi $9,576, a spread of $2,376 for the same molecule at the same 10 mg basis. If prepaid terms held across both years, MEDVi's $249 effective would total $5,976 — $1,224 under even the cheaper standing plan, with the standing caveat that two years of locked funds in this regulatory climate is a real bet, not a rounding choice. Reference rails for the same 24 months: $5,160 at the verified floor, $10,776 on brand Zepbound at maintenance, $8,376 on Wegovy flat.

Two ladders, side by side

Put both dose ladders on the same axis and the structures argue for themselves: Amble Health holds $300 on every rung (four-month titration: exactly $1,200); MEDVi holds $399 on every rung (four-month titration: exactly $1,596). A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.

Three buyers, two invoices

The month-one starter pays $300 at Amble Health versus $399 at MEDVi for the 2.5 mg rung — an early edge that holds once the ladder climbs. The settled 10 mg maintainer — the buyer our basis is built for — pays $3,600/year at Amble Health against $4,788 at the other: $1,188 of annual daylight for the same molecule and dose. The committed prepayer does best at MEDVi: $249/month effective, $2,988/year, funds up front, refund terms first.

The semaglutide board

Only MEDVi fields a verified semaglutide price here — $299/month all-in (#16 of 19) — while Amble Health focuses its published pricing on tirzepatide. For a buyer starting on the cheaper molecule with a likely upgrade later, single-molecule programs mean a future re-shop; dual-molecule ones price the whole arc.

The five normalizations, applied to this pair

1 · All-in, not advertised. Amble Health's ranked figure is $300, with no membership to add; MEDVi's ranked figure is $399, with no membership to add. 2 · Maintenance basis. Amble Health is dose-flat, so its entry and 10 mg figures coincide; MEDVi is dose-flat, so its entry and 10 mg figures coincide. 3 · Terms separated. Amble Health: standing $300, no prepaid tier; MEDVi: standing $399, prepaid $249 effective (12-month plan) — standing rates rank, prepaid effectives are labeled beside them. 4 · Evidence tiered. Amble Health: third-party-reported, read 2026-08-05; MEDVi: source-verified, read 2026-08-05. 5 · Pharmacy weighed. Amble Health names no pharmacy; MEDVi names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

Amble Health: no membership — the medication figure is the billed figure; not published; commitment: unknown. MEDVi: no membership — the medication figure is the billed figure; prepaid 12-month plan at $249/mo effective; 12-month plan applies to lowest rate; commitment: 12-month plan for the lowest rate. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

Amble Health carries third-party-reported pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. MEDVi carries source-verified pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

Moving from Amble Health to MEDVi (or back) is administratively unglamorous: complete the new program's intake, let its prescriber issue a fresh prescription to its pharmacy, and cancel the old subscription in writing — prescriptions don't transfer between telehealth programs, and neither do prepaid balances, which is the quiet reason month-to-month terms are worth their premium.

Refills, shipping, and the week-to-week reality

The unglamorous layer — how the medication actually reaches you and stays on schedule — splits like this: Amble Health: shipping unknown; consultation unknown. MEDVi: shipping included; consultation included; async visit model. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick Amble Health if the $99/month tirzepatide saving is the point. Pick MEDVi if you'll prepay for the $249 effective rate. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

If neither one fits

The dataset's bench is deep; the closest verified third options to this matchup's price band are Henry Meds at $349 (flat, no membership); TrimRx at $349 (flat, no membership); Lavender Sky Health at $352 (dose-scaled, $25 membership included) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The brand benchmark both must beat

Neither program exists in a vacuum: FDA-approved Zepbound sits at $449/month at maintenance (LillyDirect or retail KwikPens, ~$350 on TrumpRx, ~$50 for newly eligible Medicare patients), and Wegovy at a flat $349. The cheaper of these two compounded options saves $1,788/year against the Zepbound benchmark — the number that has to justify accepting a not-FDA-reviewed product, per the full trade analysis. When a compounded quote drifts above ~$350, this benchmark starts winning the argument on its own.

The verdict

On the numbers alone, Amble Health is the cheaper tirzepatide program by $99/mo. Both records, with dates and sources, live in the pricing database.